Pharmacokinetic variability and complex two-way interactions with cenobamate in patients with refractory epilepsy - PubMed
3 hours ago
- #cenobamate
- #pharmacokinetics
- #refractory-epilepsy
- Cenobamate (CNB) is a new antiseizure medication for add-on therapy in adults with refractory epilepsy.
- The study investigated pharmacokinetic variability and interactions of CNB with other antiseizure medications (ASMs).
- Data from 258 patients showed significant intraindividual and interpatient variability in CNB concentration/dose (C/D) ratios.
- Strong enzyme inducers and inhibitors affected mean CNB C/D ratios by -9% and +14%, respectively.
- CNB initiation led to significant changes in C/D ratios of desmethylclobazam (+233%), phenobarbital (+36%), lamotrigine (-28%), and carbamazepine (-26%).
- The study highlights complex, unpredictable two-way interactions in polytherapy with CNB and emphasizes the usefulness of therapeutic drug monitoring (TDM).